Oral peptides and protein-based therapeutics have been in use for more than three decades since the approval of recombinant human insulin, the first protein therapy, in 1982. Earlier, most biologic drugs were the subcutaneous biologics. However, over time, advances in delivery formulations have enabled the development of oral peptides / proteins. Owing to numerous compelling